You have no items in your shopping cart.
Ebola Virus Research Hub
Advanced reagents for Ebolavirus tracking, structural analysis, and therapeutic development. Explore highly validated antibodies, recombinant glycoproteins, biosimilars, and companion reagents.
Emerging Ebolavirus Outbreaks
As the global health community focuses on proactive pandemic preparedness, assessing the threat of emerging filoviruses remains paramount. Throughout 2026, global health authorities have been monitoring outbreaks and responding to Ebola virus disease (EVD) alerts, particularly those emerging in Central and East Africa. The silent circulation of these pathogens necessitates rapid identification methodologies.
Biorbyt provides a comprehensive portfolio of high-precision tools, from monoclonal antibodies to full-length viral glycoproteins that are designed to build the foundational knowledge required for rapid detection, viral characterization, and therapeutic intervention.
Clinical Pathology: Ebola Virus Disease (EVD)
Ebola Virus Disease (EVD) is a severe, often fatal illness in humans. It is typically transmitted to people from wild animals and spreads in the human population through human-to-human transmission.
- Zaire ebolavirus (EBOV): The most lethal species, responsible for the majority of large outbreaks, including the 2014-2016 West African epidemic.
- Sudan ebolavirus (SUDV) & Bundibugyo ebolavirus (BDBV): Highly pathogenic strains that periodically cause severe outbreaks. Treatments effective against the Zaire strain often lack efficacy against these variations.
The Diagnostic Challenge: Early symptoms of EVD heavily overlap with other common infections like malaria or typhoid fever. This overlap makes highly specific and sensitive diagnostic reagents an absolute priority to prevent misdiagnoses and accelerate containment.
Viral Structure & Entry
Ebolaviruses are filamentous, enveloped viruses containing a negative-sense, single-stranded RNA genome. The viral particle is composed of key structural proteins that serve as primary research targets:
The Glycoprotein (GP) mediates attachment and entry into host cells, making it the primary target for neutralizing antibodies and vaccine development. Inside the envelope, the Viral Protein 40 (VP40) acts as the major matrix protein driving viral assembly and budding, while the Nucleoprotein (NP) encapsidates the viral RNA genome. Minor structural differences across these proteins enable the specific detection and subtyping of viral strains.
Biosimilars & Reference Antibodies
For researchers involved in therapeutic development and comparative neutralization assays, Biorbyt offers highly validated biosimilars of key Ebola reference antibodies. These are indispensable as positive controls in ELISA and in vitro neutralization models.
Product Name | Type | SKU |
|---|---|---|
Inhibitor Antibody | ||
Monoclonal Antibody | ||
Larcaviximab Biosimilar (Zaire ebolavirus Reference Antibody) | Inhibitor Antibody | |
Porgaviximab Biosimilar (Zaire ebolavirus Reference Antibody) | Inhibitor Antibody | |
Inhibitor Antibody |
Zaire ebolavirus (EBOV) Products
Product Name | Type | SKU |
|---|---|---|
Recombinant Protein | ||
Viral VP40 protein- (strain Reston-89) (REBOV) (Reston Ebola virus) | Recombinant Protein | |
Recombinant Protein | ||
Recombinant Protein | ||
Monoclonal Antibody | ||
Rabbit Polyclonal Antibody |
Sudan & Bundibugyo ebolavirus Products
Product Name | Type | SKU |
|---|---|---|
Recombinant Protein | ||
Recombinant Protein | ||
Ebolavirus (subtype Bundibugyo) Envelope Glycoprotein 1 Protein, His Tag | Recombinant Protein | |
REBOV/SEBOV/TAFV/ZEBOV GP/Envelope glycoprotein Human Monoclonal Antibody | Monoclonal Antibody | |
Recombinant Sudan ebolavirus Envelope glycoprotein (GP), partial | Recombinant Protein | |
BDBV (Bundibugyo strain) Envelope glycoprotein Polyclonal Antibody | Rabbit Polyclonal Antibody |
Companion Bioreagents & Workflow Tools
Biorbyt offers a complete suite of reagents to complement your Ebolavirus research, allowing you to build fully validated assay workflows from a single trusted provider.
Primary Antibody Ebola Virus Monoclonal Antibody (Capture) Highly specific monoclonal antibody for targeting the Nucleoprotein (NP). Ideal for use as a capture reagent in high-fidelity sandwich ELISAs for tracking viral load in patient sera or in vivo models. Detection Antibody Ebola Virus Monoclonal Antibody (Detection) Matched detection pair for the capture antibody (orb421067), designed to accurately quantify viral load. Integrate with pre-conjugated secondary antibodies to ensure high signal-to-noise ratios. Active Protein Ebolavirus EBOV Envelope Glycoprotein Protein Full-length EBOV GP protein that can be immobilized for Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) to calculate precise binding kinetics of candidate antibodies against the viral spike. Small Molecule Inhibitor EBOV-IN-7 (compound 26) EBOV-IN-7 (compound 26) is a small molecule inhibitor of the Ebola virus, demonstrating an IC50 of 2.04 μM against EBOV-GP pseudotyped virus by blocking the GPcl/NPC1 interaction. This compound is a useful research tool for studying viral entry mechanisms and has also shown cytotoxic activity in cancer cell studies. Custom Services Custom Functional Membrane Protein Expression Services Preparation of complex multi-pass viral targets in specialized platforms like Virus-Like Particles (VLPs) or Synthetic Nanodiscs, ensuring optimized native conformations for robust entry inhibition assay development.
Bibliography
- Institute of Tropical Medicine Antwerp (ITM). Last study participant followed up in unique Ebola vaccine booster trial in DRC. 2026.
- National Academies. Are There Proven Treatments for Ebola? 2026.
- Gilchuk P. et al. Protective pan-ebolavirus combination therapy by two multifunctional human antibodies. bioRxiv. 2021.
- NanoViricides, Inc. In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC. BioSpace. 2026.
- National Institute of Allergy and Infectious Diseases (NIAID). Ebola Vaccines. NIH. 2024.
- World Health Organization (WHO). WHO makes new recommendations for Ebola treatments. 2022.